Tag Archives: immunotherapy

Curing glioblastoma with oncolytic virus and immune checkpoint blockade

Cancer immunotherapy utilizes the patient’s immune system to recognize and/or destroy tumors. The immune system has both positive activator/effector and negative inhibitory functions. Immune checkpoints are one such inhibitory function that can be overcome by immune checkpoint

New treatments for breast cancer

Now that 90% of women diagnosed with breast cancer will live at least 5 years, new treatments are aim at improving outcomes for the 10% who are not responding to current drugs and delivering treatments with less

BRAF inhibitor and interferon alpha combination for melanoma treatment

In recent years approval has been granted to many therapeutic agents for the treatment of patients with metastatic melanoma. They include small molecule inhibitors, such as the selective inhibitors of the mutant BRAF (BRAF-I) or of MEK (MEK-I), and

In vivo imaging of immunotherapeutic glioma model

Glioblastoma remains one of the deadliest diseases faced by patients, with a median survival of less than 15 months. Therapeutic advancements in the field rely heavily on animal models, and the use of human brain tumor cells

Is our immune system mistaking tumours for foetuses?

Tumours are abnormal growths of tissue where cells produced by the body get out of control and divide at a rapid and unregulated pace. And – when you think about it – embryos too are masses of

Treating prostate cancer with immunotherapy

Cancer immunotherapy induces the immune system to recognize and destroy cancer cells. These therapies can work through a number of ways but two of the most researched methods are therapeutic cancer vaccines and immune checkpoint inhibitors. Therapeutic

Does immunotherapy in Multiple Sclerosis increase the risk of developing PML?

Progressive multifocal leukoencephalopathy (PML) is a rare and life-threatening brain disease caused by the JC virus. In multiple sclerosis (MS), natalizumab (Tysabri, Biogen) was already known to substantially increase the risk for PML by suppressing the immune